{'fraction_non_alphanumeric': 0.0364963503649635, 'fraction_numerical': 0.0, 'mean_word_length': 6.456521739130435, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased Plasma brain‐derived neurotrophic factor (BDNF) as a Biomarker for Differentiating Mild Cognitive Impairment from Cognitive Healthy: A case‐control study

Across the spectrum of Alzheimer’s disease (AD), we previously conducted a meta‐analysis and concluded significantly decreased brain‐derived neurotrophic factor (BDNF) in AD. However, there are inconsistent findings on peripheral BDNF levels in mild cognitive impairment (MCI), even across different meta‐analyses, which have been attributed to the high heterogeneity caused by multiple clinical and laboratory factors. Thus, BDNF’s discriminative accuracy for identifying all‐cause MCI and its subtypes remains unknown.